Skip to main content

Cost-Effectiveness of Cabotegravir Long-Acting HIV Pre-Exposure Prophylaxis (PrEP): A Systematic Review of Modelling Studies

In brief

US and Asia-Pacific models put cabotegravir's needed price cuts at 24% to 88%

Across 11 modelling studies, long-acting cabotegravir prevented more HIV infections than oral prevention, especially where HIV incidence was high and daily pill adherence was poor. At current prices, US and Asia-Pacific models generally found it not cost-effective, while African models were more favorable at lower prices. Its value depends on local costs, risk and delivery assumptions.

Journal
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (Q1)
Published
12 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Fortune B Effiong, Dimeji A Olawuyi, Benjamin B Effiong, Anuoluwapo V Adeyemi, Emmanuel Ekpor, Roseline D Dine, et al.
PMID
43020268
DOI
10.1016/j.jval.2026.10.012

Why clinicians should know about it

Abstract

OBJECTIVES: Cabotegravir long-acting injectable (CAB-LA) is a promising non-oral pre-exposure prophylaxis (PrEP) for HIV prevention, especially where daily oral adherence is poor. Despite superior efficacy, CAB-LA's high price raises concerns about economic value and implementation across settings. This study reviewed modelling studies on CAB-LA's cost-effectiveness as PrEP across diverse populations and settings. METHODS: We searched PubMed, Scopus, Web of Science, Embase and Cochrane Library (2015-2025), assessing CAB-LA's cost-effectiveness versus oral PrEP or no PrEP. Eligible studies reported incremental cost-effectiveness ratios, cost per HIV infection averted, or cost per quality-adjusted life year (QALY) or disability-adjusted life year gained. Reporting quality was assessed using the CHEERS 2022 checklist. Results were narratively synthesized due to heterogeneity. RESULTS: Eleven modelling studies across sub-Saharan Africa, the United States, and Asia-Pacific showed that CAB-LA averted more HIV infections than oral PrEP, especially in high-incidence, low-adherence populations. In high-risk U.S. populations, CAB-LA averted about 71,000 infections and gained 4.65 million QALYs. In Africa, CAB-LA became economically favourable under lower acquisition-cost assumptions, although cost-effective prices varied across models, populations, price years and thresholds. U.S. and Asia-Pacific models found CAB-LA not cost-effective at current prices, requiring 24-88% price reductions. Sensitivity and scenario analyses showed that cost-effectiveness estimates were responsive to CAB-LA price, HIV incidence, ART coverage, adherence, persistence, and programme-delivery assumptions. CONCLUSION: CAB-LA cost-effectiveness is context dependent and generally more favourable at lower prices, higher-incidence populations, and poor oral PrEP adherence. Wider adoption may require strategies to improve economic value, equitable access, and implementation, especially in resource-constrained settings.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.